JACC:高敏肌钙蛋白+冠脉CTA,确诊隐匿性冠心病的“黄金搭档”

2021-10-02 MedSci原创 MedSci原创

冠状动脉疾病(CAD)是全世界最常见的死亡原因。

冠状动脉疾病(CAD)是全世界最常见的死亡原因。许多CAD患者一直未被诊断,直到他们因急性胸痛到医院就诊。目前的评估策略主要是通过床边临床评估、心电图和连续的心肌肌钙蛋白检测来排除急性心肌梗死

然而,即使排除了急性心肌梗死,仍有相当一部分患者可能仍有潜在的CAD,并有将来发生不良心脏事件的风险。选择此类患者进行进一步检查的最佳方法仍不确定。

现在人们越来越认识到,高敏心肌肌钙蛋白(hs-cTnI)浓度在正常参考范围内可以帮助对疑似急性冠脉综合征患者进行分流。此前有专家确定并验证了5ng/L的排除阈值,该阈值可使疑似急性冠状动脉综合征患者在发病时被确定为低风险的人数达到最大化,且30天内心肌梗死或心脏死亡的阴性预测值大于99.5%。

为了评估hs-cTnI在排除心肌梗死后的患者选择进一步检查的作用,来自英国BHF血管科学中心的专家开展了一项前瞻性队列研究,相关结果发表在《美国心脏病学会》JACC杂志上。

研究对象为到急诊科就诊的疑似急性冠脉综合征患者,且hs-cTnI浓度低于特定性别的第99%。患者以2:1的方式招募,按hs-cTnI峰值浓度高于和低于5ng/L的风险分层阈值进行分层。所有患者在出院后都接受了冠状动脉计算机断层扫描(CCTA)。

总体而言,招募了250名患者(61.4±12.2岁,31%为女性),其中62.4%(250名患者中的156名)患有冠状动脉疾病(CAD)。与hs-cTnI浓度<5 ng/L的患者相比,hs-cTnI浓度中等的患者(介于5 ng/L和特定性别的第99百分位数之间)更有可能患有CAD,风险增加2.33倍(71.9% [120/167] vs 43.4% [36/83];OR= 3.33;95% CI:1.92-5.78)。

不同hs-cTnI浓度亚组发生CAD的风险

相反,心绞痛症状和CAD之间没有关联(63.2% [67/106] vs 61.8% [89/144];OR=0.92;95% CI:0.48-1.76)。大多数CAD患者以前没有诊断(53.2%;83/156),在接受CCTA之前没有使用抗血小板和他汀类药物治疗(63.5%;99/156)。

在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。

 

参考文献:

Troponin-Guided Coronary Computed Tomographic Angiography After Exclusion of Myocardial Infarction. J Am Coll Cardiol. 2021 Oct, 78 (14) 1407–1417

评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
    2022-05-09 windight
  2. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
    2022-09-07 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
    2021-10-04 许安
  8. [GetPortalCommentsPageByObjectIdResponse(id=1850133, encodeId=92f8185013310, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Mon May 09 15:07:38 CST 2022, time=2022-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854996, encodeId=d47018549963f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Sep 07 06:07:38 CST 2022, time=2022-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1936115, encodeId=c7f2193611588, content=<a href='/topic/show?id=1908984822d' target=_blank style='color:#2F92EE;'>#隐匿性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98482, encryptionId=1908984822d, topicName=隐匿性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b71f2500114, createdName=1179102698_36768926, createdTime=Sat Apr 02 22:07:38 CST 2022, time=2022-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326867, encodeId=cfe5132686e59, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493776, encodeId=83681493e76bb, content=<a href='/topic/show?id=3dd430933df' target=_blank style='color:#2F92EE;'>#冠脉CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30933, encryptionId=3dd430933df, topicName=冠脉CTA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=631f9090927, createdName=tcm102hq, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618479, encodeId=26f716184e9c2, content=<a href='/topic/show?id=5dbc98480ef' target=_blank style='color:#2F92EE;'>#隐匿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98480, encryptionId=5dbc98480ef, topicName=隐匿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1caf19894563, createdName=41514493@qq.com, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1630067, encodeId=0eb6163006ed6, content=<a href='/topic/show?id=6439309329e' target=_blank style='color:#2F92EE;'>#冠脉CT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30932, encryptionId=6439309329e, topicName=冠脉CT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e3821444802, createdName=许安, createdTime=Mon Oct 04 13:07:38 CST 2021, time=2021-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057339, encodeId=2dfa105e3398a, content=<a href='/topic/show?id=0cb1510519b' target=_blank style='color:#2F92EE;'>#心梗#</a>在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51051, encryptionId=0cb1510519b, topicName=心梗)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTInOuicIVN8Y32NO4Q53Zpd86ObmNp2WIotichCD0qQHaUBeHj7hgwQBCzX7ce4aEw5ZP8icQQfLH9Zw/132, createdBy=4ec21734756, createdName=1def6e10m76(暂无匿称), createdTime=Mon Oct 04 07:21:52 CST 2021, time=2021-10-04, status=1, ipAttribution=)]
    2021-10-04 1def6e10m76(暂无匿称)

    #心梗#在排除心肌梗死的患者中,与低hs-cTnI浓度相比,中度hs-cTnI浓度的患者CAD的可能性大3倍。在这样的患者中,CCTA可以帮助识别那些隐匿的CAD,并进行有针对性的预防治疗,从而改善临床结果。

    0

相关资讯

JAMA Psychiatry: 有氧运动或艾司西酞普兰治疗冠心病焦虑患者

艾司西酞普兰对患有冠心病的焦虑患者是安全有效的,同时有氧运动对改善冠心病患者焦虑有益

EHJ:孰优孰略?冠脉三支病变或左主干病变患者介入与开胸手术的比较

在3VD和/或LMCAD患者中,MAG可能是更理想的CABG配置,以实现比PCI更低的长期全因死亡率。

护士主导的电子健康护理干预措施能够改善冠心病患者预后

护士主导的电子健康心脏康复计划对改变行为风险因素及提高健康相关生活质量有效。

JAMA Psychiatry:当心!冠心病患者可能得了“双心病”!

艾司西酞普兰治疗焦虑对减少冠心病患者的焦虑是安全和有效的。

梅斯心血管疾病进展 (009期)

编者按:梅斯医学将定期进行汇总,帮助大家概览心血管领域最新进展。下面是呈现给大家的最新一期的心血管进展。enjoy~

拓展阅读

Nature子刊 复旦大学附属中山医院葛均波院士团队揭示肠道菌群通过胆汁酸调控血小板活化和动脉粥样硬化血栓形成

该研究表明,肠道微生物群-胆汁酸-TGR5信号轴调控血小板活化和动脉粥样硬化性血栓形成,进而提出了靶向肠道微生物群和/或改变胆汁酸代谢可能是治疗冠心病相关动脉血栓形成的一种有潜力的治疗方法。

粗大右冠脉急性闭塞大量血栓溶栓成功后再闭塞

48 岁男性因反复胸闷胸痛入院,有高血压等病史。冠脉造影示右冠脉及前降支瘤样扩张、闭塞伴血栓。经开通右冠脉等治疗,后续多次造影并调整用药,因症状和指标变化对药物进行增减与替换。

冠心病风险降低近30%!JAMA子刊:两大血脂指标同时改善,获益或更大

LDL-C是ASCVD危险因素,现有治疗达标率有限且有残余风险。研究表明,APOC3与LDL-C相关靶点水平同时降低,冠心病风险进一步降低且呈叠加效应,或为高危患者治疗带来新方向。

小欧探案记|冠心病合并肾功能不全的血脂管理方案

联合ω-3治疗方案有效降低了心血管风险,为冠心病、代谢综合征合并高甘油三酯血症的患者提供了有效的管理策略。

提心吊胆的后扩张

52 岁男性因发作性胸痛胸闷 2 年加重伴晕厥入院,有糖尿病史,诊断有心脏多方面问题。冠脉造影处理 RCA,治疗中多次扩张出现胸痛、ST 段抬高,经药物处理缓解,总结了糖尿病合并冠心病介入治疗要点。

心血管科高频疾病系列之——冠心病篇

本文汇总了冠心病近期的研究进展、优质的指南解读、实用的医学公式和课程等优质内容,全方位助力临床医生,点击立即开启学习之旅。